Research work · 2020

Avelumab

National Cancer Institute

Definitions

Abstract

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities.Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1).T his inhibits the activation of PD-1 and its downstream signaling pathways.T his may restore immune function through the activation of cytotoxic T -lymphocytes (CT Ls) targeted to PD-L1-overexpressing tumor cells.In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells.PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T -cells, negatively regulates T -cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.

Download PDF

DOI: 10.32388/1cmybx